Literature DB >> 14623169

Direct lung delivery of para-aminosalicylic acid by aerosol particles.

N Tsapis1, D Bennett, K O'Driscoll, K Shea, M M Lipp, K Fu, R W Clarke, D Deaver, D Yamins, J Wright, C A Peloquin, D A Weitz, D A Edwards.   

Abstract

Para-aminosalicylic acid (PAS), a tuberculostatic agent, was formulated into large porous particles for direct delivery into the lungs via inhalation. These particles possess optimized physical properties for deposition throughout the respiratory tract, a drug loading of 95% by weight and physical stability over 4 weeks at elevated temperatures. Upon insufflation in rats, PAS concentrations were measured in plasma, lung lining fluid and homogenized whole lung tissue. Systemic drug concentrations peaked at 15 min, with a maximum plasma concentration of 11+/-1 microg/ml. The concentration in the lung lining fluid was 148+/-62 microg/ml at 15 min. Tissue concentrations were 65+/-20 microg/ml at 15 min and 3.2+/-0.2 microg/ml at 3h. PAS was cleared within 3 h from the lung lining fluid and plasma but was still present at therapeutic concentrations in the lung tissue. These results suggest that inhalation delivery of PAS can potentially allow for a reduction in total dose delivered while providing for higher local and similar peak systemic drug concentrations as compared to those obtained upon oral PAS dosing. Similar particles could potentially be used for the delivery of additional anti-tuberculosis agents such as rifampicin, aminoglucosides or fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623169     DOI: 10.1016/j.tube.2003.08.016

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  12 in total

Review 1.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

2.  Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Authors:  Jean C Sung; Lucila Garcia-Contreras; Jarod L Verberkmoes; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

3.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

Review 4.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

5.  Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Authors:  Jean C Sung; Danielle J Padilla; Lucila Garcia-Contreras; Jarod L Verberkmoes; David Durbin; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Pharm Res       Date:  2009-04-30       Impact factor: 4.200

6.  Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation.

Authors:  Amit Rawat; Quamrul H Majumder; Fakhrul Ahsan
Journal:  J Control Release       Date:  2008-03-21       Impact factor: 9.776

7.  Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Authors:  L Garcia-Contreras; J Fiegel; M J Telko; K Elbert; A Hawi; M Thomas; J VerBerkmoes; W A Germishuizen; P B Fourie; A J Hickey; D Edwards
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 8.  Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery.

Authors:  Sachin Gharse; Jennifer Fiegel
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 9.  Pharmaceutical aerosols for the treatment and prevention of tuberculosis.

Authors:  Shumaila N M Hanif; Lucila Garcia-Contreras
Journal:  Front Cell Infect Microbiol       Date:  2012-09-07       Impact factor: 5.293

10.  Novel drug delivery systems: desired feat for tuberculosis.

Authors:  Kirtipal Kaur; Anuj Gupta; R K Narang; R S R Murthy
Journal:  J Adv Pharm Technol Res       Date:  2010-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.